Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Phase 1/2 Unknown 52 enrolled Swedish Medical Center AstraZeneca · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.

Timeline

Start: 2012-08
Primary completion: 2018-12
Completion: 2019-12

Publications

Rivkin SE, Moon J, Iriarte DS, Bailey E, Sloan HL, Goodman GE, BonDurant AE, Velijovich D, Wahl T, Jiang P, Shah CA, Drescher C, Fer MF, Kaplan HG, Ellis ED. Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. Int J Gynecol Cancer. 2019 Feb;29(2):325-333. doi: 10.1136/ijgc-2018-000035. Epub 2019 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaparib	Small molecule	50 mg	Oral
Subject	Olaparib	Small molecule	100 mg	Oral
Subject	Olaparib	Small molecule	150 mg	Oral
Subject	Olaparib	Small molecule	200 mg	Oral
Background	Carboplatin	Small molecule	—	—
Background	Paclitaxel	Small molecule	60 mg/m2	—

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications